-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Crohn's disease (CD) is an inflammatory bowel disease (IBD) characterized by chronic inflammatory recurrent attacks in the gastrointestinal tract.
often diarrhea and fatigue can lead to a significant reduction in health-related quality of life.
conventional wisdom, CD treatment is aimed at alleviating clinical symptoms, but there is growing evidence that clinical symptoms may not be fully consistent with endoscopic activity in CD patients.
use of objective biomarkers as an alternative indicator of mucous membrane healing has become a hot topic in academic research.
studies have shown that high levels of C-reactive protein (CRP) concentrations are associated with increased anti-tumor necrosis group (TNF) antibody therapy response in CD patients, but serological markers are less sensitive and less specific to CD.
and other studies have shown that fecal calcium (FC) is associated with disease activity in endoscopes.
, the relationship between biomarker cut-off levels and mucous membrane improvement has not yet been fully established.
study aims to study this in greater depth.
researchers conducted subgroup analysis of randomized CD patients for up to 48 weeks of endoscopic severity index≥ (CDEIS) and no deep ulcers, and sensitivity analysis of patients with cRP and/or FC elevation at baseline, based on different groups of CRP and lt;5 mg/L and FC-250μg/g or ≥250μg.
the association between endoscope endpoints and biomarker cut-off values using a card-side test.
results showed that the proportion of patients who reached the primary endpoint of CDEIS and 4 without deep ulcers was significantly higher (74% ;P and 0.001) and that CRP was more effective.
association between FC and 250 μg/g and improved endoscopic effects was independent of the location of the disease, although the association was greatest observed in recidectal colon disease.
the sensitivity/specificity of cdEIS s/4 was 72%/63%, and the positive/negative prediction was 86%/42%.
, the researchers concluded that the threshold value of FC slt;250 μg/g is a useful alternative to CD mucosa healing.
.
